P. aeruginosa Burn Infections: Pathogenesis and Treatment

  • Ian Alan Holder
Chapter
Part of the Infectious Agents and Pathogenesis book series (IAPA)

Abstract

Prior to the late 1950s burn deaths related to infection were caused by the gram-positive bacteria Staphylococcus aureus and Streptococcus pneumoniae.1,2 Improved methods of fluid therapy introduced between 1950 and 1960 allowed survival of many severely burned patients over the initial period of thermal injury; this increased survival time coupled with the introduction of antibiotics capable of controlling gram-positive sepsis caused a shift in septic complications to those caused by gram-negative bacteria.3–5 Infections caused by Pseudomonas aeruginosa were particularly severe, with high mortality rates.6 In the intervening years, P. aeruginosa continued to cause the most severe, life-threatening infections in burn patients, in spite of the introduction of a wide variety of antibiotics devised specifically for their antipseudomonal activity. One U.S. burn institution reported that from 1959 to 1983, mortality from P. aeruginosa infection was 77%; this was 28% higher than the mortality predicted on the basis of severity of injury in the infected patients.? Another burn unit reported that between 1969 and 1988, while percent recovery of Escherichia coli and Klebsiella—Enterobacter from the wounds of burn patients was similar to that of P. aeruginosa, P. aeruginosa caused more fatal septicemia than the combined deaths from all other gram-negative bacteria.8 The mortality figures cited in these studies point out the unique host: parasite interaction that is present in P. aeruginosa infection in burned individuals.

Keywords

Pseudomonas Aeruginosa Burned Site Burned Patient Silver Sulfadiazine Hageman Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Langohr, J. L., Owen, C. R., and Cope, O., 1947, Bacteriologic study of burn wounds, Ann. Surg. 125:452–455CrossRefGoogle Scholar
  2. 2.
    Lynch, J. B., Kim, K. A., Larson, D. L., Doyle, J. E., and Lewis, S. R., 1971, Changing patterns of mortality in burns, Plast. Reconstr. Surg. 48:329–332.PubMedCrossRefGoogle Scholar
  3. 3.
    Yow, E. M., 1952, Development of Proteus and Pseudomonas infections during antibiotic therapy, J.A.M.A. 149:1184–1186CrossRefGoogle Scholar
  4. 4.
    Tumbusch, W. T., Vogel, E. H. Butkiewicz, J. V., Graber, C. D., Larson, D. L., and Mitchell, E. T., 1961, Septicemia in burn injury, J. Trauma 1:22–27.Google Scholar
  5. 5.
    Stone, H. H., 1966, Review of Pseudomonas sepsis in thermal burns, Ann. Surg. 163:297–301.PubMedCrossRefGoogle Scholar
  6. 6.
    Moncrief, J. A., and Rivera, J. A., 1958, The problem of infection in burns by resistant micro-organisms with a note on the use of bacitracin, Ann. Surg. 147:295–299.PubMedCrossRefGoogle Scholar
  7. 7.
    Speller, D. E. E., 1980, Hospital infection by multi-resistant gram-negative bacilli, J. Antimicrob. Chemother. 6:168–170.PubMedCrossRefGoogle Scholar
  8. 8.
    Holder, I. A., 1990, Microbiology of the burn compromised patient, in: Pathogenesis of Wound and Biomaterial Associated Infections (T. Wadstrom, I. Eliasson, I. A. Holder, and A. Ljungh, eds.), Springer-Verlag, London, pp. 91–100.CrossRefGoogle Scholar
  9. 9.
    McManus, A. T., 1989, Pseudomonas aeruginosa: A controlled burn pathogen? in: Pseudomonas aeruginosa Infection,Antibiotics Chemotherapy, Volume 42 (N. Høiby, S. S. Pederson, G. Shand, G. Miring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp. 103–108.Google Scholar
  10. 10.
    Wasserman, D., Schlotterer, M., Lebreton, E., Levy, J., and Guelfi, M. D.,1989, Use of topically applied silver sulphadiazine plus cerium nitrate in major burns, Burns 15: 257–260.CrossRefGoogle Scholar
  11. 11.
    Koo, D. S., Gu, X. M., Zhen, S., DeZhen, Z., Shi, S. W., and Xiang, S. J., 1989, Assessment of topical therapy of the burn wound with silver sulphadiazine after its use for 15 years in a burn unit, Burns 15:193–196.PubMedCrossRefGoogle Scholar
  12. 12.
    Bang, R. L., and Saif, J. K., 1989, Mortality from burns in Kuwait, Burns 15:315–321.PubMedCrossRefGoogle Scholar
  13. 13.
    Shulman, J. A., Terry, P. M., and Hough, C. E., 1971, Colonization with a gentamicin resistant Pseudomonas aeruginosa pyocine type 5 in a burn unit, J. Infect. Dis. 124:S18–S23.PubMedCrossRefGoogle Scholar
  14. 14.
    Sogaard, H., Zimmerman-Nielsen, C., and Siboni, K., 1974, Antibiotic-resistant gram-negative bacilli in a urological ward for male patients during a nine-year period: Relationship to antibiotic consumption, J. Infect. Dis. 130:646–650.PubMedCrossRefGoogle Scholar
  15. 15.
    Holder, I. A., 1976, Gentamicin resistant Pseudomonas aeruginosa in a burns unit, J. Antimicrob. Chemother. 2:309–316.PubMedCrossRefGoogle Scholar
  16. 16.
    LeFrock, J. L., Molavi, A., and Smith, B. R., 1984, Current use of aminoglycosides, Infect. Surg. 3:57–65.Google Scholar
  17. 17.
    Pruitt, B. A., 1983, Treating burn and soft tissue infections, Infect. Surg. 2:625–650.Google Scholar
  18. 18.
    Holder, I. A., Vanderpool, I., and Wesselman, J., 1985, Para-chloro-meta-xylenol (PCMX): A new, potential topical antimicrobial agent, J. Burn Care Rehab. 6:58–61.CrossRefGoogle Scholar
  19. 19.
    Holder, I. A., Schwab, M., and Jackson, L., 1979, Eighteen months of routine topical antimicrobial susceptibility testing of isolates from burn patients: Results and conclusions, J. Antimicrob. Chemother. 5:455–463.PubMedCrossRefGoogle Scholar
  20. 20.
    Fox, C. L., Vyasa Rao, T. N., Azmeth, R.., Gandhi, S. S., and Modak, S., 1990, Comparative evaluation of zinc sulfadiazine and silver sulfadiazine in burn wound infection, J. Burn Care Rehab. 11:112–117.CrossRefGoogle Scholar
  21. 21.
    Wachtel, T. L., 1987, Topical antimicrobials, in: Burns in Children (H. E. Carvajal, D. H. Parks, eds.), Year Book Medical Publishers, Inc., Chicago, pp. 106–118.Google Scholar
  22. 22.
    Waisbren, B. A., 1976, Treatment of severe burns, Compr. Ther. 2:33–42.Google Scholar
  23. 23.
    Moyer, C. A., Brentano, L., Gravens, D. L., Margraf, H. W., and Monafo, W. W., 1965, Treatment of large human burns with 0.5% silver nitrate solution, Arch. Surg. 90:812–867.PubMedCrossRefGoogle Scholar
  24. 24.
    Shuck, J. M., Einfeldt, L. E., and Trainor, M. P., 1972, Sulfamylon solution dressings in the management of burn wounds: Preliminary clinical report, J. Trauma 12:999–1002.PubMedCrossRefGoogle Scholar
  25. 25.
    Holder, I. A., 1989, The wet disc antimicrobial solution assay: An in vitro method to test efficacy of antimicrobial solutions for topical use, J. Burn Care Rehab. 10:203–208.CrossRefGoogle Scholar
  26. 26.
    Holder, I. A., 1988, Pseudomonas immunotherapy, Serodiag. Immunother. 2:7–16.CrossRefGoogle Scholar
  27. 27.
    Liu, P. V., Abe, Y., and Bates, J. L., 1961, The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis, J. Infect. Dis. 108:218–227.PubMedCrossRefGoogle Scholar
  28. 28.
    Liu, P. V., 1966, The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis: II. Effects of lecithinase and protease, J. Infect. Dis. 116:112–116.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu, P. V., 1966, The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis: III. Identity of the lethal toxins produced in vitro and in vivo, J. Infect. Dis. 116:481–489.PubMedCrossRefGoogle Scholar
  30. 30.
    Morihara, K., 1963, Pseudomonas aeruginosa proteinase: I. Purification and general properties, Biochem. Biophys. Acta 73:113–124.CrossRefGoogle Scholar
  31. 31.
    Morihara, K., Tsuzuki, H., Oka, T., Inoue, H., and Ebata, M., 1965, Pseudomonas aeruginosa elastase. Isolation, crystallization, and preliminary characterization, J. Biol. Chem. 240: 3295–3304.PubMedGoogle Scholar
  32. 32.
    Liu, P. V., Yoshii, S., and Hsieh, H., 1973, Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A, J. Infect. Dis. 128:514–519.PubMedCrossRefGoogle Scholar
  33. 33.
    Liu, P. V., and Hsieh, H., 1973, Exotoxins of Pseudomonas aeruginosa. III. Characteristics of antitoxin A, J. Infect. Dis. 128:520–526.PubMedCrossRefGoogle Scholar
  34. 34.
    Callahan, L. T., III, 1974, Purification and characterization of Pseudomonas aeruginosa exotoxin, Infect. Immun. 9:113–118.PubMedGoogle Scholar
  35. 35.
    Atik, M., Liu, P. V., Hanson, B. A., Amini, S., and Rosenberg, C. E., 1968, Pseudomonas exotoxin shock. A preliminary report of studies in dogs, J.A.M.A. 205:134–140.PubMedCrossRefGoogle Scholar
  36. 36.
    Pavlovskis, O. R., and Gordon, E. B., 1972, Pseudomonas aeruginosa exotoxin: Effect on cell cultures, J. Infect. Dis. 125:631–636.PubMedCrossRefGoogle Scholar
  37. 37.
    Pavlovskis, O. R., and Shackelford, A. H., 1974, Pseudomonas aeruginosa exotoxin in mice: Localization and effect on protein synthesis, Infect. Immun. 9:540–546.PubMedGoogle Scholar
  38. 38.
    Pavlovskis, O. R., Voelker, F. A., and Shackelford, A. H., 1976, Pseudomonas aeruginosa exotoxin in mice: Histopathology and serum enzyme changes,J.Infect. Dis. 133:253–259.PubMedCrossRefGoogle Scholar
  39. 39.
    Iglewski, B. H., and Kabat, D., 1975, NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin, Proc. Natl. Acad. Sci. U.S.A. 72:2284–2288.PubMedCrossRefGoogle Scholar
  40. 40.
    McRipley, R. J., and Garrison, D. W., 1964, Increased susceptibility of burned rats to Pseudomonas aeruginosa, Proc., Soc. Exp. Biol. Med. 115:336–338.Google Scholar
  41. 41.
    Liedberg, C. F., 1960, Antibacterial resistance in burns. I. The effect of intraperitoneal infection on survival and the frequency of septicemia. An experimental study in the guinea pig, Acta Chir. Scand. 120:88–94.Google Scholar
  42. 42.
    Stieritz, D. D., and Holder, I. A., 1975, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Description of a burned mouse model,J. Infect. Dis. 131:668–691.CrossRefGoogle Scholar
  43. 43.
    Stieritz, D. D., and Holder, I. A., 1978, Experimental studies of the pathogenesis of Pseudomonas aeruginosa infection: Evidence for the in vivo production of a lethal toxin,J.Med. Microbiol. 11:101–109.PubMedCrossRefGoogle Scholar
  44. 44.
    Bartell, P. E., Orr, T. E., and Garcia, M., 1968, The lethal events in experimental Pseudomonas aeruginosa infection in mice, J. Infect. Dis. 118:165–172.PubMedCrossRefGoogle Scholar
  45. 45.
    Saelinger, C. B., Snell, K., and Holder, I. A., 1977, Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: Direct evidence of toxin production during Pseudomonas infection of burned skin tissues, J. Infect. Dis. 136:555–561.PubMedCrossRefGoogle Scholar
  46. 46.
    Pavlovskis, O. R., Pollack, M., Callahan, L. T., III, and Iglewski, B. H., 1977, Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections, Infect. Immun. 18:596–602.PubMedGoogle Scholar
  47. 47.
    Holder, I. A., and Haidaris, C. G., 1979, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Extra-cellular protease and elastase as in vivo virulence factor. Can. J. Microbiol. 45:593–599.CrossRefGoogle Scholar
  48. 48.
    Snell, K., Holder, I. A., Leppla, S. A., and Selinger, C. B., 1978, Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa, Infect. Immun. 19:839–845.PubMedGoogle Scholar
  49. 49.
    Cryz, S. J., Furer, E., and Germanier, R., 1983, Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by transfer of antitoxin A, anti-elastase, and anti-lipopolysaccharide, Infect. Immun. 39:1072–1079.PubMedGoogle Scholar
  50. 50.
    Pavlovskis, O. R., Edman, D. C., Leppla, S. H., Wretlind, B., Lewis, L. R., and Martin, K. E., 1981, Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids, Infect. Immun. 32:681–689.PubMedGoogle Scholar
  51. 51.
    Walker, H. L., and Mason, Jr., A. D., 1968, A standard animal burn, J. Trauma 8:1049–1051.PubMedCrossRefGoogle Scholar
  52. 52.
    Walker, H. L., McLeod, C. G., Jr., Leppla, S. H., and Mason, Jr., A. D., 1979, Evaluation of Pseudomonas aeruginosa toxin A in experimental rat burn wound sepsis, Infect. Immun. 25: 828–830.PubMedGoogle Scholar
  53. 53.
    Fox, C. L., Jr., Sampath, A. C., and Stanford, J. W., 1970, Virulence of Pseudomonas infection in burned rats and mice, Arch. Surg. 101:508–512.PubMedCrossRefGoogle Scholar
  54. 54.
    Pollack, M., Callahan, III, L. T., and Taylor, N. S., 1976, Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: Evidence for in vivo toxin production during Pseudomonas infection of burned skin tissues,J.Infect. Dis. 136:555–561.Google Scholar
  55. 55.
    Pollack, M., and Taylor, N. S., 1977, Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay, J. Clin. Microbial. 6:58–61.Google Scholar
  56. 56.
    Pollack, M., and Young, L. S., 1979, Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man, J. Clin. Microbiol. 63:276–286.Google Scholar
  57. 57.
    Crowe, K. E., Bass, J. A., Young, V. M., and Straus, D. C., 1982, Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients, J. Clin. Microbiol. 15:115–122.PubMedGoogle Scholar
  58. 58.
    Klinger, J. D., Straus, D. C., Hilton, C. E., and Bass, J. A., 1978, Antibodies to protease and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay, J. Infect. Dis. 138:49–58.PubMedCrossRefGoogle Scholar
  59. 59.
    Cross, A. S., Sadoff, J. C., Iglewski, B. H., and Sokol, P. A., 1980, Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans, J. Infect. Dis. 142:538–546.PubMedCrossRefGoogle Scholar
  60. 60.
    Kawaharajo, K., Homma, J.Y., Aoyama, Y., Okada, E., and Morihara, K., 1975, In vivo studies on protease and elastase from Pseudomonas aeruginosa, Jpn. J. Exp. Med. 45:89–100.PubMedGoogle Scholar
  61. 61.
    Meinke, G., Barum, J., Rosenberg, B., and Berk, R., 1970, In vivo studies with the partially purified protease (elastase) from Pseudomonas aeruginosa, Infect. Immun. 2:583–589.PubMedGoogle Scholar
  62. 62.
    Fetzer, A. E., Werner, A. S., and Hagstrom, J. W. C., 1967, Pathologic features of Pseudomonas pneumonia, Am. Rev. Resp. Dis. 96:1121–1130.PubMedGoogle Scholar
  63. 63.
    Kawaharajo, K., Abe, C., Homma, J. Y., Kawane, M., Gotoh, T., Tanaka, N., and Morihara, K., 1974, Corneal ulcers caused by protease and elastase from Pseudomonas aeruginosa, Jpn. J. Exp. Med. 44:435–442.PubMedGoogle Scholar
  64. 64.
    Gray, L. D., and Kreger, A. S., 1975, Rabbit corneal damage produced by Pseudomonas aeruginosa infection, Infect. Immun. 12:419–432.PubMedGoogle Scholar
  65. 65.
    Kreger, A. S., Griffin, I. K., 1974, Physiochemical fractionation of extracellular cornea-damaging proteases of Pseudomonas aeruginosa, Infect. Immun. 9:828–834.PubMedGoogle Scholar
  66. 66.
    Neely, A. N., and Holder, I. A., 1987, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Treatment using Pseudomonas hyperimmune globulin plus minocycline and effects of minocycline on protease elaboration, Serodiag. Immunother. 1: 193–200.CrossRefGoogle Scholar
  67. 67.
    Holder, I. A., and Neely, A. N., 1989, Combined host and specific anti-Pseudomonasdirected therapy for Pseudomonas aeruginosa infections in burned mice: Experimental results and theoretic considerations, J. Burn Care Rehab. 10:131–137.CrossRefGoogle Scholar
  68. 68.
    Pavlovskis, O. R., and Wretlind, B., 1979, Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection, Infect. Immun. 24:181–187.PubMedGoogle Scholar
  69. 69.
    Kawaharajo, K., Homma, J. Y., Aoyama, Y., and Morihara, K., 1975, In vivo studies on protease and elastase from Pseudomonas aeruginosa, Jpn. J. Exp. Med. 45:89–100.PubMedGoogle Scholar
  70. 70.
    Heck, L. W., Morihara, K., McRae, W. B., and Miller, E. J., 1986, Specific cleavage of human type III and IV collagens by Pseudomonas aeruginosa elastase, Infect. Immun. 51:115–118.PubMedGoogle Scholar
  71. 71.
    Heck, L. W., Morihara, K., and Abrahamson, D. R.., 1986, Degradation of soluble laminin and depletion of tissue-associated basement membrane laminin by Pseudomonas aeruginosa elastase and alkaline protease, Infect. Immun. 54:149–153.PubMedGoogle Scholar
  72. 72.
    Cicmanec, J. E., and Holder, I. A., 1979, Growth of Pseudomonas aeruginosa in normal and burned skin extract: Role of extracellular proteases, Infect. Immun. 25:477–483.PubMedGoogle Scholar
  73. 73.
    Morihara, K. Tsuzuki,H., and Oda,K., 1979, Protease and elastase of Pseudomonas aeruginosa: Inactivation of human plasma α1-proteinase inhibitor, Infect. Immun. 24: 189–193.Google Scholar
  74. 74.
    Morihara, K., Tsuzuki, H., Harada, M., and Iwata, T., 1984, Purification of human plasma a i-proteinase inhibitor and its inactivation by Pseudomonas aeruginosa elastase, J. Biochem. 95:795–804.PubMedGoogle Scholar
  75. 75.
    Catanese, J., and Kress, L. F., 1984, Enzymatic inactivation of human plasma Cl-inhibitor and α1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase, Biochim. Biophys. Acta 789:37–43.PubMedCrossRefGoogle Scholar
  76. 76.
    Theander, T. G., Kharazmi, A., Pedersen, B. K., Christensen, L. D., Tvede, N., Poulsen, L. K., Odum, N., Svenson, M., and Bendtzen, K., 1988, Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases, Infect. Immun. 56:1673–1677.PubMedGoogle Scholar
  77. 77.
    Schultz, D. R.., and Miller, K.. D., 1974, Elastase of Pseudomonas aeruginosa: Inactivation of complement components and complement-derived chemotactic and phagocytic factors, Infect. Immun. 10:128–135.PubMedGoogle Scholar
  78. 78.
    Horvat, R.., and Parmely, M. J., 1988, Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity, Infect. Immun. 56:2925–2932.PubMedGoogle Scholar
  79. 79.
    Döring, G., Obernesser, H.. J., and Botzenhart, K.., 1981, Extra-cellular toxins of Pseudomonas aeruginosa. II. Effect of two proteases on human immunoglobulin IgG, IgA and secretory IgA, Zentralbi. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. I. Orig. Reihe A. 249: 89–98.Google Scholar
  80. 80.
    Döring, G., Dalhoff, A., Vogel, O., Brunner, H., Droge, U., and Botzenhart, K., 1984, In vivo activity of proteases of Pseudomonas aeruginosa in a rat model,J. Infect. Dis. 149:532–537.PubMedCrossRefGoogle Scholar
  81. 81.
    Holder, I. A., and Wheeler, R., 1984, Experimental studies of the pathogenesis of infections owning to Pseudomonas aeruginosa: Elastase, an IgG protease, Can.J. Microbiol. 30:1118–1124.PubMedCrossRefGoogle Scholar
  82. 82.
    Holder, I. A., and Neely, A. N., 1989, Pseudomonas elastase acts as a virulence factor in burned hosts by Hageman factor-dependent activation of the host kinin cascade, Infect. Immun. 57:3345–3348.PubMedGoogle Scholar
  83. 83.
    Molla, A., Yammamoto, T., Akaike, T., Miyoshi, S., and Maeda, H., 1989, Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteases, J. Biol. Chem. 264:10589–10594.PubMedGoogle Scholar
  84. 84.
    Holder, I. A., and Neely, A. N., 1990, Hageman factor dependent kinin activation in burns and its theoretical relationship to post burn immunosuppression syndrome and infection,J.Burn Care Rehab., in press.Google Scholar
  85. 85.
    Bjornson, A. B., and Bjornson, H. S., 1984, Theoretical interrelationship among immunologic and hematologic sequelae of thermal injury, Rev. Infect. Dis. 6:704–714.PubMedCrossRefGoogle Scholar
  86. 86.
    Sato, H., and Okinaga, K., 1987, Role of pili in the adherence of Pseudomonas aeruginosa to mouse epidermal cells, Infect. Immun. 55:1774–1778.PubMedGoogle Scholar
  87. 87.
    Sato, H., Okinaga, K.., and Saito, H., 1988, Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection, Microbiol. Immunol. 32:131–139.PubMedGoogle Scholar
  88. 88.
    McManus, A. T., Moody, E. E., and Mason, A. D., 1980, Bacterial motility: A component in experimental Pseudomonas aeruginosa burn wound sepsis, Burns 6:235–239.CrossRefGoogle Scholar
  89. 89.
    Montie, T. C., Doyle-Huntzinger, D., Craven, R.. C., and Holder, I. A., 1982, Loss of virulence associated with absence of flagellum in an isogeneic mutant of Pseudomonas aeruginosa in the burned mouse model, Infect. Immun. 38:1296–1298.PubMedGoogle Scholar
  90. 90.
    Craven, R.. C., and Montie, T. C., 1981, Motility and chemotaxis of three strains of Pseudomonas aeruginosa used for virulence studies, Can. J. Microbial. 27:458–460.CrossRefGoogle Scholar
  91. 91.
    Drake, D., and Montie, T. C., 1988, Flagella, motility and invasive virulence of Pseudomonas aeruginosa, J. Gen. Microbiol. 134:43–52.PubMedGoogle Scholar
  92. 92.
    Ansorg, R., 1978, Flagella specific H antigenic schema of Pseudomonas aeruginosa, Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. I. Orig. Reihe A. 242:228–238.Google Scholar
  93. 93.
    Montie, R.. C., Craven, R. C., and Holder, I. A., 1982, Flagellar preparations from Pseudomonas aeruginosa: Isolation and characterization, Infect. Immun. 35:281–288.PubMedGoogle Scholar
  94. 94.
    Holder, I. A., and Naglich, J. G., 1986, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Immunization using divalent flagella preparations, J. Trauma 26:118–122.PubMedCrossRefGoogle Scholar
  95. 95.
    Holder, I. A., Wheeler, R.., and Montie, T. C., 1982, Flagellar preparations from Pseudomonas aeruginosa: Animal protection studies, Infect. Immun. 35:276–280.PubMedGoogle Scholar
  96. 96.
    Drake, D., and Montie, T. C., 1987, Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum, Can. J.Microbiol. 35:755–763.CrossRefGoogle Scholar
  97. 97.
    Anderon, T. R., and Montie, T. C., 1989, Flagellar antibody stimulated opsonophagocytosis of Pseudomonas aeruginosa associated with response to either a-or b-type flagellar antigen, Can. J. Microbiol. 35:890–894.CrossRefGoogle Scholar
  98. 98.
    Neely, A. N., Nathan, E., and Highsmith, R. F., 1988, Plasma proteolytic activity following burns, J. Trauma 28:362–367.PubMedCrossRefGoogle Scholar
  99. 99.
    Edmonds, E., Suskind, R. R., MacMillan, B. G., and Holder, I. A., 1972, Epidemiology of Pseudomonas aeruginosa in a burns hospital: Evaluation of serological, bacteriophage and pyocin typing methods, Appt. Microbiol. 24:213–218.Google Scholar
  100. 100.
    Edmonds, P., Suskind, R. R., MacMillan, B. G., and Holder, I. A., 1972, Epidemiology of Pseudomonas aeruginosa in a burns hospital: Surveillance by a combined typing system, Appt. Microbiol. 24:219–225.Google Scholar
  101. 101.
    Holder, I. A., 1977, Epidemiology of Pseudomonas aeruginosa in a burns hospital, in: Pseudomonas aeruginosa: Ecological Aspects and Patient Colonization (V. M. Young, ed.), Raven Press, New York, pp. 77–95.Google Scholar
  102. 102.
    Collins, M. S., Tsay, G. C., Hector, R. E., Roby, R. E., and Dorsey, J. H., 1986, Immunoglobulin G: Potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo, Rev. Infect. Dis. 8:S420–S425.PubMedCrossRefGoogle Scholar
  103. 103.
    Burch, R. M., Farmer, S. C., and Steranka, L. R., 1990, Bradykinin receptor antagonists, Med. Res. Rev. 10:237–269.PubMedCrossRefGoogle Scholar
  104. 104.
    Honda, E., Homma, J. Y., Abe, C., Tanamoto, K., Noda, H., and Yanagawa, R., 1977, Effects of the common protective antigen (OEP) and toxoids of protease and elastase from Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink, Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. a Orig. Reihe A. 237:297–309.Google Scholar
  105. 105.
    Hirao, Y., and Homma, J. Y., 1978, Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection, Jpn. J. Exp. Med. 48:41–51.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Ian Alan Holder
    • 1
  1. 1.Shriners Burns InstituteCincinnatiUSA

Personalised recommendations